FibroBiologics (FBLG) Stock Analysis
NASDAQHealthcareBiotechnology
What FibroBiologics does
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
Key metrics
ETFs linked to FBLG
Broad-market and Healthcare sector ETFs an investor holding FibroBiologics is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how FBLG fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze FBLG in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for FibroBiologics?
- FibroBiologics trades under the ticker FBLG on NASDAQ.
- Which exchange is FBLG listed on?
- FBLG is listed on NASDAQ.
- What sector does FibroBiologics operate in?
- FibroBiologics is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze FBLG in a portfolio?
- PortView shows FBLG's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.